QINLOCK

This brand name is authorized in Austria, Canada, Estonia, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Poland, United Kingdom, United States

Active ingredients

The drug QINLOCK contains one active pharmaceutical ingredient (API):

1 Ripretinib UNII 9XW757O13D - RIPRETINIB

Ripretinib is a novel tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase and PDGFRA kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF. Read about Ripretinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
QINLOCK Tablet	European Medicines Agency (EU)	MPI, EU: SmPC
QINLOCK Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX19		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02500833
Country: EE	Ravimiamet	Identifier(s): 1867743, 1867754
Country: FR	Base de données publique des médicaments	Identifier(s): 67629484
Country: HK	Department of Health Drug Office	Identifier(s): 67004
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9032
Country: IT	Agenzia del Farmaco	Identifier(s): 049792017, 049792029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093697, 1093698
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100462443
Country: US	FDA, National Drug Code	Identifier(s): 73207-101